Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Harue Igarashi"'
Autor:
Yoshiaki Ohtsu, Yumi Nishiguchi, Makoto Takahashi, Tomoko Arakawa, Keiko Nakai, Koji Arai, Hisanori Hara, Katsutomo Hata, Ryosuke Ochiai, Junji Komaba, Masanari Mabuchi, Takeru Yamaguchi, Akemi Nagao, Nozomu Koseki, Takahiro Nakamura, Hisao Shimizu, Harue Igarashi, Yoshihisa Sano, Yosuke Kawai, Naoaki Murao, Ryosuke Yoshinaga, Hitoshi Uchiyama
Publikováno v:
Bioanalysis. 13:1653-1657
Approximately 300 people associated with pharmaceutical industries, contractors, academic institutions and regulatory authorities attended the 12th Japan Bioanalysis Forum Symposium. The webinar was conducted from 9 to 11 March 2021. The theme of the
Autor:
Ryutaro Shimamura, Debra J. Tompson, Annette S. Gross, Hirofumi Ogura, Takashi Nagakubo, Nicola Scott, Edward P. Cannons, Hiroko Ino, Atsushi Nakano, Michalis Kostapanos, Carwyn Davies, Marcy Powell, Harue Igarashi
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Funder: GlaxoSmithKline; doi: http://dx.doi.org/10.13039/100004330
BACKGROUND AND OBJECTIVES: GSK2982772 is an oral small-molecule RIPK1 inhibitor with potential therapeutic efficacy in immune-mediated inflammatory diseases (IMIDs). An inter-eth
BACKGROUND AND OBJECTIVES: GSK2982772 is an oral small-molecule RIPK1 inhibitor with potential therapeutic efficacy in immune-mediated inflammatory diseases (IMIDs). An inter-eth
Autor:
Rui Ohashi, Takahiro Nakamura, Yoshiro Saito, Kosuke Saito, Seiji Tanaka, Masaaki Kakehi, Tamiki Mori, Hiroyuki Kakuo, Ryosuke Nakamura, Mizuki Horiuchi, Hiroyuki Yokoi, Harue Igarashi, Hiroyuki Shimizu, Masataka Katashima, Yoshiaki Ohtsu, Yutaka Yasuda, Takashige Okayama
Publikováno v:
Bioanalysis. 13(18)
Biomarkers are an important drug developmental tool. Assessment of quantitative analytical methods of biomarkers is not included in any regulatory documents in Japan. Use of biomarkers in clinical evaluations and supporting the post-marketing evaluat
Autor:
Takeru Yamaguchi, Yoshiaki Ohtsu, Tomoko Arakawa, Hisanori Hara, Hiroshi Kamimori, Yoshihisa Sano, Sakiko Suzuki, Masaaki Kakehi, Hitoshi Uchiyama, Masanari Mabuchi, Yosuke Kawai, Junji Komaba, Jun Hosogi, Harue Igarashi, Akemi Nagao, Takahiro Nakamura, Yumi Nishiguchi, Keiko Nakai
Publikováno v:
Bioanalysis. 11:1303-1308
The Japan Bioanalysis Forum Symposium was held on 12–14 February 2019 (Yokohama, Japan), in celebration of its 10th anniversary, and over 370 participants from pharmaceutical industries, contractors, academia and regulatory authorities from home an
Publikováno v:
Bioanalysis. 11:611-617
Autor:
Yosuke Kawai, Junji Komaba, Takahiro Nakamura, Keiko Nakai, Hiroshi Kamimori, Harue Igarashi, Yoshihisa Sano, Jun Hosogi, Takeru Yamaguchi
Publikováno v:
Bioanalysis. 10:1467-1471
The ninth Japan Bioanalysis Forum symposium took place at tower hall Funabori, Tokyo, Japan, between 6 and 8 February, 2018. Bioanalytical scientists from the pharmaceutical industry, CROs, academia and regulatory bodies had many meaningful and relev
Autor:
Romina A. Nand, Annette S. Gross, Hiroko Ino, Hiroshi Itoh, Harue Igarashi, Hirofumi Ogura, Yotaro Numachi, Takayuki Iida
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(6)
The pharmacokinetics of pyrimethamine have been evaluated in various populations but have not been reported in subjects of Japanese ancestry following administration as a single-agent tablet. Furthermore, although pyrimethamine pharmacokinetics after
Autor:
Thales Cardoso, Mohamed Ben M’Barek, Jenny Lin, Lisa Geisler, Harue Igarashi, Jay Schaefgen, Subramanian Ramachandran, Vera Hillewaert, Michael J. Redrup
Publikováno v:
The AAPS Journal. 18:290-293
The importance of appropriate sample management in regulated bioanalysis is undeniable for clinical and non-clinical study support due to the fact that if the samples are compromised at any stage prior to analysis, the study results may be affected.
Autor:
Anthony Cahn, Harue Igarashi, Yotaro Numachi, Hirofumi Ogura, Takumi Terao, Robert Wilson, Hiroko Ino
Publikováno v:
Clinical pharmacology in drug development. 8(1)
The aim of the study was to assess the safety, tolerability, and pharmacokinetics of single and repeat doses of nemiralisib administered via a dry powder inhaler to healthy Japanese subjects. This was a single-center, double-blind, randomized, placeb
Publikováno v:
Clinical Pharmacology in Drug Development. 4:262-269
This phase 1 study characterized the safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod and its metabolite GSK198602 following single and repeat doses of oral losmapimod in healthy Japanese volunteers. Subjects (n = 41) receiv